September 27, 2017
LYON, France & NEW YORK–(BUSINESS WIRE)–The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, will announce its 2017 Half-Year Results on Monday, 2 October, after market.
On the following day, Tuesday, 3 October, Medicrea will participate in a meeting organized by SFAF (French Society of Financial Analysts) to present the Company’s strategy and results.
The upcoming dates announced on the original schedule remain otherwise unchanged:
• 2017 Third Quarter sales
October 12, 2017*
• 2017 Annual sales
|January 11, 2018*|
*Subject to modification. After market.
Next publication: 2017 Half-Year Results on 2 October, after market.
About Medicrea (www.Medicrea.com)
Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 100,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.
For further information, please visit: Medicrea.com.
Medicrea is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572